The US Food and Drug Administration late Wednesday authorized booster doses of the Pfizer/BioNTech COVID-19 vaccine for people ages 65 and up. Also eligible for boosters will be those ages 18 to 64 who are at high risk of severe COVID-19 or at high risk from frequent occupational or institutional exposures to SARS-CoV-2, such as healthcare workers and teachers.
The single booster dose should only be given at least six months after the two initial doses. The authorization comes as an amendment to an Emergency Use Authorization.
The FDA’s authorization largely
→ Continue reading at Ars Technica